Shilpa Medicare Limited Share Price and Company Fundamentals
Last traded: Last Friday at 9:59 AM
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Key Metrics
PE ratio
27.97
PB ratio
2.54
Dividend yield
0.16%
Beta
0.07
Market cap
₹61.77B
Enterprise value
₹64.82B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 998 |
| Website | https://www.vbshilpa.com |
| Mailing address | Shilpa House #12-6-214/A-1 Hyderabad Road Raichur 584135 India |
| Phone / Fax | 91 85 3223 8704 / 91 85 3223 8876 |
Dividends
Dividend yield
0.16%
Dividend amount
₹0.50
Payout ratio
4.42%
5Y Avg. yield
-%
Shilpa Medicare Limited paid ₹0.50 dividend and the ex-dividend date was 17 Sep 2025.The dividend payout ratio is 4.42%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.SHILPAMED dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on Shilpa Medicare Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm | MD & Director | 63 | |
| Mr. Sharath Reddy Kalakota M.Pharma | VP of Projects & Operations and Whole-Time Director | 58 | |
| Mr. Alpesh Maheshkumar Dalal | Chief Financial Officer | 49 | |
| Pramod Kumar | Senior Vice President of Technical | 62 | |
| Mr. Monish Shah | Head of Investor Relations | ||
| Ms. Ritu Tiwary | Company Secretary & Compliance Officer | 48 | |
| Mr. P. V. Narasimha Rao | Chief Human Resource Officer | ||
| Mr. Vinay Konaje | Business Head of Biologics | 52 | |
| Ms. Rajyashri Karur Ramakrishnan | Chief Scientific Officer of Biologicals | 60 | |
| Dr. Jayant Karajgi | Chief Operating Officer of Formulations | 58 |
Profitability and management effectiveness
Profit margin
10.47%
Operating margin
20.49%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Shilpa Medicare Limited is 61.77B and its enterprise value is 64.82B. The enterprise value to revenue ratio of SHILPAMED is 4.52. The enterprise value to EBITDA ratio of SHILPAMED is 17.13.
The SHILPAMED's stocks Beta value is 0.07 making it 93% less volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Shilpa Medicare Limited (NSE:SHILPAMED) Frequently Asked Questions
1. What is Shilpa Medicare Limited's Stock Symbol?
Shilpa Medicare Limited trades on NSE under the ticker symbol "SHILPAMED".
2. What is Shilpa Medicare Limited's stock price today?
One share of SHILPAMED stock can currently be purchased for approximately ₹315.8.
3. How can I contact Shilpa Medicare Limited?
Shilpa Medicare Limited's mailing address is Shilpa House #12-6-214/A-1 Hyderabad Road Raichur 584135 India. The company can be reached via phone at 91 85 3223 8704.
4. What is Shilpa Medicare Limited's official website?
The official website of Shilpa Medicare Limited is https://www.vbshilpa.com.